FDA Approves OTC Naloxone Spray to Broaden Opioid Overdose Treatment Access

The U.S. Food and Drug Administration has authorized Rextovy, a naloxone hydrochloride nasal spray, for over-the-counter sales. This decision aims to increase public access to a vital medication that can quickly reverse opioid overdose effects. The approval is part of ongoing efforts to address the national public health crisis of overdose deaths.